BR112015017100A2 - processo para o preparo do agente antitumoral 6-(7-((1-aminociclopropil) metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1- naftamida e seu cristalino - Google Patents

processo para o preparo do agente antitumoral 6-(7-((1-aminociclopropil) metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1- naftamida e seu cristalino

Info

Publication number
BR112015017100A2
BR112015017100A2 BR112015017100A BR112015017100A BR112015017100A2 BR 112015017100 A2 BR112015017100 A2 BR 112015017100A2 BR 112015017100 A BR112015017100 A BR 112015017100A BR 112015017100 A BR112015017100 A BR 112015017100A BR 112015017100 A2 BR112015017100 A2 BR 112015017100A2
Authority
BR
Brazil
Prior art keywords
yloxy
methoxy
methyl
aminocyclopropyl
methoxyquinolin
Prior art date
Application number
BR112015017100A
Other languages
English (en)
Inventor
Paul Chen Guoqing
Original Assignee
Advenchen Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advenchen Pharmaceuticals Llc filed Critical Advenchen Pharmaceuticals Llc
Publication of BR112015017100A2 publication Critical patent/BR112015017100A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

resumo “processo para o preparo do agente antitumoral 6-(7-((1-aminociclopropil) metoxi)-6-metoxiquinolin-4- iloxi)-n-metil-1-naftamida e seu cristalino”, por tratar-se a presente invenção de um novo processo para sintetizar 6-(7-((1-aminociclopropil)-metoxi)-6- metoxiquinolin-4-iloxi)-n-metil-1-naftamida (al3810) através da desproteção do substituto benzil 1-((6-metoxi-4-(5-(metilcarbamoil)naftaleno-2-iloxi)quinolin-7-iloxi)- metil)cicloprilcarbamato (fórmula i) sob uma condição ácida fraca ou diluída. uma forma cristalina estável de 6-(7-((1-aminociclopropil)-metoxi)-6-metoxiquinolin-4- iloxi)-n-metil-1-naftamida foi também preparada. 1/1
BR112015017100A 2013-01-18 2014-01-17 processo para o preparo do agente antitumoral 6-(7-((1-aminociclopropil) metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1- naftamida e seu cristalino BR112015017100A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361754516P 2013-01-18 2013-01-18
PCT/US2014/011948 WO2014113616A1 (en) 2013-01-18 2014-01-17 Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline

Publications (1)

Publication Number Publication Date
BR112015017100A2 true BR112015017100A2 (pt) 2017-07-11

Family

ID=51210076

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017100A BR112015017100A2 (pt) 2013-01-18 2014-01-17 processo para o preparo do agente antitumoral 6-(7-((1-aminociclopropil) metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1- naftamida e seu cristalino

Country Status (18)

Country Link
US (1) US9783498B2 (pt)
EP (1) EP2945931A4 (pt)
JP (1) JP2016506917A (pt)
KR (1) KR102275034B1 (pt)
CN (2) CN111454206A (pt)
AU (1) AU2014207482A1 (pt)
BR (1) BR112015017100A2 (pt)
CA (1) CA2896898A1 (pt)
EA (1) EA201591205A1 (pt)
HK (2) HK1213563A1 (pt)
IL (1) IL239877B (pt)
MA (1) MA38274A1 (pt)
MX (1) MX2015008543A (pt)
PH (1) PH12015501571A1 (pt)
RU (1) RU2015127211A (pt)
SG (1) SG11201505389WA (pt)
WO (1) WO2014113616A1 (pt)
ZA (1) ZA201505043B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311030B (zh) 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
KR102426138B1 (ko) 2014-07-14 2022-07-28 어드벤첸 라보라토리스 난징 리미티드 ＰＩ3Ｋ, ｍＴＯＲ 저해제로서 융합된 퀴놀린 화합물
WO2016091168A1 (zh) 2014-12-09 2016-06-16 正大天晴药业集团股份有限公司 抗非小细胞肺癌的喹啉衍生物
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
WO2017011363A1 (en) 2015-07-11 2017-01-19 Advenchen Pharmaceuticals, LLC Fused quinoline compunds as pi3k/mtor inhibitors
CN107296811B (zh) 2016-04-15 2022-12-30 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物
CN111936467B (zh) 2018-03-02 2022-02-18 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途
CN110483392A (zh) * 2018-05-14 2019-11-22 上海海和药物研究开发有限公司 合成n-保护的喹啉-7-基氧基甲基环丙基胺衍生物的方法及合成中间体
CN110483393A (zh) * 2018-05-14 2019-11-22 上海海和药物研究开发有限公司 德立替尼的晶型
CN115160221A (zh) * 2022-07-26 2022-10-11 上海歆贻医药科技有限公司 德立替尼晶型化合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
IT1393351B1 (it) * 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
EP2786750B2 (en) * 2011-12-02 2023-06-28 EA Pharma Co., Ltd. Agent for reducing adverse side effects of kinase inhibitor
EP2916827B1 (en) * 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects

Also Published As

Publication number Publication date
EA201591205A1 (ru) 2015-12-30
CA2896898A1 (en) 2014-07-24
IL239877A0 (en) 2015-08-31
ZA201505043B (en) 2017-11-29
MX2015008543A (es) 2015-11-16
SG11201505389WA (en) 2015-08-28
WO2014113616A1 (en) 2014-07-24
EP2945931A1 (en) 2015-11-25
HK1213563A1 (zh) 2016-07-08
AU2014207482A1 (en) 2015-08-13
KR20150108871A (ko) 2015-09-30
HK1217328A1 (zh) 2017-01-06
RU2015127211A (ru) 2017-03-03
CN104936946A (zh) 2015-09-23
KR102275034B1 (ko) 2021-07-12
EP2945931A4 (en) 2016-10-12
CN111454206A (zh) 2020-07-28
US20150353496A1 (en) 2015-12-10
JP2016506917A (ja) 2016-03-07
IL239877B (en) 2018-07-31
PH12015501571A1 (en) 2015-10-05
MA38274A1 (fr) 2017-02-28
US9783498B2 (en) 2017-10-10

Similar Documents

Publication Publication Date Title
BR112015017100A2 (pt) processo para o preparo do agente antitumoral 6-(7-((1-aminociclopropil) metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1- naftamida e seu cristalino
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
MX2016007346A (es) Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio.
BR112015022861A2 (pt) inibidores de bromodomínio
PH12016500024A1 (en) Bromodomain inhibitor
MY194074A (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
MX353806B (es) Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
RS54492B1 (en) KINASE INHIBITOR REGULATING THE SIGNAL PATH OF APOPTOSIS
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
BR112015021524A2 (pt) derivados de sulfonil quinolina e usos dos mesmos
NZ719169A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
UA115868C2 (uk) Гетероциклічні сполуки, лікарські засоби, які містять зазначені сполуки, їх застосування і способи їх одержання
MX2016007440A (es) Inhibidores del bromodominio.
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
MX2016007810A (es) Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa.
MX2015012386A (es) Inhibidores de la cinasa cdk9.
AR092772A1 (es) Derivado de 7-azaindol
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
EA201891866A1 (ru) N,N-ДИМЕТИЛ-3-[[5-(3-МЕТИЛ-2-ОКСО-1-ТЕТРАГИДРОПИРАН-4-ИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-8-ИЛ)-2-ПИРИДИЛ]ОКСИ]ПРОПАН-1-АМИНОКСИД В КАЧЕСТВЕ МОДУЛЯТОРА АТМ-КИНАЗЫ (МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ) ДЛЯ ЛЕЧЕНИЯ РАКА

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]